国产人α_1型基因工程干扰素治疗小儿乙型肝炎病毒相关性肾炎（HBV－GN）的初步观察  

PRELIMINARY STUDY ON THE TREATMENTOF CHILDREN HBV ASSOCIATED GLOMERU-LONEPHRITIS WITH HUMAN RECOMBINANTα_1INTERFERON (rhIFNα_1 )

作　　者：方利君[1] 盛芳芸[1] 徐虹[1] 郭怡清[1] 贺新玉[1] 

机构地区：[1]上海医科大学儿科医院

出　　处：《中华肾脏病杂志》1994年第6期329-331,378,共4页Chinese Journal of Nephrology

摘　　要：我们报道应用国产重组人α１干扰素治疗小儿乙肝病毒相关性肾炎（ＨＢＶ－ＧＮ）三例患者临床表现均为肾病综合征，结合临床特征，病理检查及肾组织中ＨＢＶＤＮＡ的提取均符合ＨＢＶ－ＧＮ的诊断标准。应用α１干扰素的剂量为３００万ｕ／ｍ￣２体表面积，疗程４个月，发现一例血清ＨＢＡｇ较快转阴，尿蛋白减少，血ＣＤ＿４／ＣＤ＿８恢复正常，另一例血清ＨＢＡｇ始终阳性，血ＣＤ＿３上升，尿蛋白消失。提示该药有抑制ＨＢＶ病毒在被感染细胞内复制及增殖作用，并可调节、改善机体的免疫功能。hree cases of HBV associated glomerulonephritis(HBV-GN) are treated by huinan recombinant interferon (rhIFNa1) made in China. All of these caseshave manifestation of nephrotic syndrome. Their clinical characteristics , pathological findings and molecularsurvey of HBV DNA in renal tissues fulfill the criteriafor diagnosis of HBVGN. The dosage of rhIFNa, is 3× 106u/m2 of surface area and the standard course isfour months. Two cases have been completed for thetreatment. In one case, the serum HBAg has beenrapidly converted from positive to negative, the urineprotein reduced and the ratio of CD4/CD8 turn to nor-mal. In the other case, though the serum HBAg re-mains positive, CD3 increases and urine protein disap-pears. It is implicated that rhIFNα_1 might possibly in-hibat the replication of HBV in infected cells as well ashave some regulatory effect to improve the host im-munological function.

关 键 词：乙肝病毒相关性肾炎 Α干扰素 乙肝病毒抗原 T细胞亚群 

分 类 号：R692.39[医药卫生—泌尿科学]